BMO Capital Markets Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Neurocrine Biosciences (NASDAQ:NBIX) had its target price lowered by analysts at BMO Capital Markets from $147.00 to $140.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “market perform” rating on the stock. BMO Capital Markets’ price objective indicates a potential upside of 11.49% from the stock’s previous close.

NBIX has been the topic of a number of other reports. TD Cowen increased their price objective on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Mizuho raised their price target on Neurocrine Biosciences from $146.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. Canaccord Genuity Group increased their target price on Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. JPMorgan Chase & Co. lowered their target price on shares of Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Monday, January 12th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $175.00 price objective (up previously from $173.00) on shares of Neurocrine Biosciences in a report on Thursday, January 8th. Fifteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $177.67.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock traded down $11.87 on Thursday, reaching $125.58. The stock had a trading volume of 1,784,454 shares, compared to its average volume of 1,135,184. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $160.18. The company has a 50 day simple moving average of $141.39 and a 200 day simple moving average of $140.58. The stock has a market cap of $12.52 billion, a P/E ratio of 30.02, a price-to-earnings-growth ratio of 0.65 and a beta of 0.31.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the sale, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at approximately $18,632,008.90. This represents a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Leslie V. Norwalk sold 5,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $152.23, for a total value of $761,150.00. Following the transaction, the director owned 7,429 shares of the company’s stock, valued at $1,130,916.67. The trade was a 40.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 61,966 shares of company stock worth $8,625,166. Corporate insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds have recently made changes to their positions in the company. Loomis Sayles & Co. L P grew its holdings in shares of Neurocrine Biosciences by 5.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 169,220 shares of the company’s stock valued at $24,000,000 after purchasing an additional 8,404 shares in the last quarter. Andra AP fonden purchased a new position in Neurocrine Biosciences in the 4th quarter valued at approximately $9,630,000. DJE Kapital AG purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $28,000. Great Lakes Advisors LLC increased its position in shares of Neurocrine Biosciences by 4.1% during the fourth quarter. Great Lakes Advisors LLC now owns 3,752 shares of the company’s stock worth $532,000 after acquiring an additional 147 shares during the period. Finally, Aviva PLC boosted its holdings in Neurocrine Biosciences by 5.7% in the fourth quarter. Aviva PLC now owns 70,423 shares of the company’s stock valued at $9,988,000 after purchasing an additional 3,784 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Multiple analysts remain constructive—several firms reiterated Buy/Outperform and maintain high price targets (Bank of America reiterated Buy with a $190 target; Needham, HC Wainwright and others also kept Buy ratings), signaling continued Wall Street confidence in the franchise and pipeline. Bank of America reiterates Buy
• Positive Sentiment: Analyst tweaks were modest—Wedbush slightly raised its target and other firms trimmed targets by small amounts while keeping Buy ratings, indicating revisions are more calibration than negative turns. Analyst target movement (Benzinga)
• Neutral Sentiment: Revenue and product sales remained strong: Q4 total revenue roughly $805.5M (+~28% YoY) and full‑year 2025 net product sales ~$2.83B; management gave Ingrezza 2026 net product sales guidance of $2.7–$2.8B. These results support the company’s commercial durability but leave execution and margin questions. PR Newswire: Q4 results & guidance
• Negative Sentiment: EPS missed consensus materially (reported $1.88 vs. Street ~$2.36), which is the primary near‑term catalyst for the selloff—investors reacted to the earnings miss despite revenue growth. MarketBeat: Earnings miss
• Negative Sentiment: Management’s commentary and some analyst notes described cautious 2026 outlook/near‑term cost pressures — that tone, together with the EPS miss, magnified downside pressure. Investing.com: cautious 2026 guidance
• Negative Sentiment: Reported insider selling and some institutional rebalancing were highlighted in aftermarket coverage, which can add mechanical selling pressure on a down day. QuiverQuant: insider selling and stock reaction

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.